Navigation Links
Plato BioPharma, Inc Appoints New Board Member
Date:2/10/2011

WESTMINSTER, Colo., Feb. 10, 2011 /PRNewswire/ -- Plato BioPharma, Inc ("PBI") announced today that its Board of Directors has appointed a new director, Mr. Dan Mitchell, effective November 1, 2010.  Dan has been in the venture capital industry for over 25 years focused on early stage opportunities primarily in healthcare and biotech industries.  Dan also serves on the Boards of Directors of Kalypto Medican, GlobeImmune, and Apoplogic.

"Dan is an outstanding addition to the Plato BioPharma Board," said Craig F. Plato, CEO and founder of Plato BioPharma. "His substantial experience and financial background will serve both our shareholders and customers well as PBI continues to grow and expand its capabilities and offerings."

Dan began his venture career at the First National Bank of Chicago's Institutional Venture Capital Fund, and then co-founded Capital Health Venture Partners, a healthcare-focused venture fund in 1985.  In 1996 he co-founded Sequel Venture Partners ("Sequel"). Sequel invests in seed and early stage opportunities primarily in the Front Range of Colorado.  His prior investments include Pyxis (acq. by Cardinal Health), Genomic Solutions (acq. by Harvard Bioscience), Tetra Technologies, Quovadx, and Myogen (acq. by Gilead Sciences, Inc).

Founded in 2009, Plato BioPharma, Inc is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker, and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.

Bob Leahy 1-303-506-6960


'/>"/>
SOURCE Plato BioPharma, Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. New PLATO Sub-Analysis of CABG Patients Presented at ACC
2. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
3. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
4. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
5. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
6. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
7. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
8. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
9. Cayenne Medical, Inc. Appoints David B. Springer President & CEO
10. SYNARC Appoints Ciaran Cooper as Vice President, Business Development
11. Onyx Pharmaceuticals Appoints Bill Ringo to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be featured ... publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an Emergency ... He also serves as Medical Director for the Bureau of Emergency Medical Services and ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... for large animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO ... cartilage development and joint health in horses at the immunologic level. , The ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing ... advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered ... few as 16 months and for as little as $14,528. These changes will enable ...
Breaking Medicine News(10 mins):